Altimmune, Inc. (ALT) Presents at Morgan Stanley 23rd Annual

President, CEO & Director Absolutely. Well, thank you for having us. We appreciate it. I'm Vipin Garg, President and CEO of Altimmune; and my colleague, Dr. Scott Harris, our Chief Medical Officer. Happy, excited to tell you about Altimmune. So we are developing a GLP-1 glucagon dual receptor agonist for the treatment of serious liver diseases such as MASH. We'll talk more about that. But really, the idea is this -- the drug is called pemvidutide is rationally designed to have both direct effects in the liv ...